British Journal of Cancer · 2019 · 159 citations · 17 references
MedicineOncologyPathologyImmunotherapyMolecular OncologyNeoplasiaCancer BiomarkersCancer ImmunotherapyImmuno-oncology BiomarkersTherapy Response AssessmentTumor GradingTumor MarkersImmunotherapy Response AssessmentImmunotherapy Response BiomarkersIntratumor HeterogeneityPositive Predictive ValuePredictive Biomarker AssessmentProgrammed Death-ligand 1 BiomarkerResponse To ImmunotherapyTherapy Response Evaluation
Intratumor heterogeneity may contribute to the ambiguous clinical results on PD-L1 status as a predictor for immunotherapy response in patients with HNSCC. This decreases the utility of PD-L1 expression from single tumour biopsies as a predictive biomarker. In this prospective study, intratumor heterogeneity of PD-L1 expression in HNSCC was investigated with both Tumour Proportion Score (TPS) and Combined Positive Score (CPS). Thirty-three whole surgical specimens from 28 patients with HNSCC were included. PD-L1 expression in six random core biopsies from each surgical specimen was used to assess the concordance between multiple biopsies and the negative predictive value of a single negative core biopsy. With 1% cut off, 36% of the specimens were concordant with TPS and 52% with CPS. With a 50% cut-off value the concordance was 70% with TPS and 55% with CPS. Defining a tumour as positive if just a single-one of the biopsies was positive, the negative predictive value (NPV) of a single negative core biopsy was 38.9 and 0% (1% cut off), and 79.9% and 62.8% (50% cut off) for TPS and CPS, respectively. In conclusion, PD-L1 positivity varies markedly within the tumour, both with TPS and CPS, challenging the utility of this biomarker.
17
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text
Medicine, Oncology, Pharmacotherapy +17